People

Intranasal drug developer Vistagen has announced the appointment of Elissa Cote as Chief Corporate Development Officer. According to her LinkedIn page, Cote served as a strategic advisor to Narcan nasal spray developer Emergent Biosolutions from January 2023 to… Read more . . .

Nocion Therapeutics, which is developing inhaled dry powder taplucainium (NOC-110, formerly NTX-1175) for the treatment of chronic cough, has announced the appointment of Matthew Frankel as Chief Medical Officer. Frankel was most recently Chief Medical… Read more . . .

CDMO Kindeva has announced the appointment of Melanie Cerullo as Chief Quality Officer. Cerullo was most recently Chief Quality and Regulatory Officer at Recipharm’s ReciBioPharm business unit and previously served in quality roles at Wave Life… Read more . . .

Nebulizer maker HCmed has announced the appointment of Chris Vernall as its new Executive VP of Business Development. Vernall started his career as an inhalation scientist at Nanopharm and later returned to Nanopharm as Director… Read more . . .

Orbia Fluor & Energy Materials (formerly Koura) has announced the appointments of a new General Manager, Global Commercial Director, UK Operations Director, and Technical Manager for its Pharma Business Unit, which includes Zephex brand MDI… Read more . . .

Intranasal epinephrine developer Bryn Pharma announced that former Aerami Therapeutics Chief Operating Officer Joshua Ziel has joined the company as CEO, succeeding Sandy Loreaux. Prior to joining Aerami in 2022, Ziel held management positions at… Read more . . .

Inhaled drug developer Transpire Bio has announced the hires of Timothy Lutz as VP of Manufacturing and Operations; Stuart Loesch as Chief Commercial Officer; and Todd Sunstrom as Head of Quality Assurance. The company recently… Read more . . .

UK-based Synairgen, which is developing SNG001 inhaled interferon-beta-1a, announced that former Chiesi Global Head of Drug Development Mark Parry-Billings will succeed Simon Shaw as Chairman of the Board. Shaw will retire in October 2024. Prior to… Read more . . .

Nasal drug developer Leyden Laboratories announced that former Moderna vaccine development executive Jintanat Ananworanich has joined the company as Chief Medical Officer. Ananworanich was most recently Executive Director of clinical development at Moderna, and her… Read more . . .